Kyverna Corrects P-Value, Files $100M Raise as Shares Plunge 32%

Introduction

Kyverna Therapeutics Inc. (NASDAQ: KYTX) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Emeryville, California. The company is focused on developing chimeric antigen receptor T-cell (CAR T) therapies aimed at resetting the immune system of patients with B-cell-driven autoimmune diseases such as stiff person syndrome, myasthenia gravis, lupus nephritis, multiple sclerosis, and systemic sclerosis.

Corporate Structure

Kyverna operates as a public company in the biotechnology research sector. It employs between 51 and 200 people and maintains active clinical trial sites across the United States and Europe. Its lead investigational product, KYV-101 (also known as miv-cel), is an autologous CD19-directed CAR T therapy. Additional candidates include KYV-102 (autologous, rapid manufacturing) and KYV-201 (allogeneic). Kyverna holds a license and collaboration agreement with Intellia Therapeutics, Inc. to advance allogeneic CAR cell therapies.

CAR T-cell therapy by Anton Darius

Recent Developments and News

• November 13, 2025: Kyverna hosted a webinar on CAR T-cell therapy in generalized myasthenia gravis, highlighting its ongoing Phase 3 KYSA-6 trial open to patients with AChR or MuSK antibody-positive disease.
• November 17, 2025: CEO Warner Biddle presented at the Jefferies Global Healthcare Conference in London; a live webcast was made available via the company’s investor relations site.
• December 15, 2025: Kyverna held a conference call to discuss topline data from the registrational Phase 2 KYSA-8 trial of KYV-101 in stiff person syndrome (SPS).
• December 15, 2025: The company released its Q3 2025 financial results.
• December 17, 2025: A free-writing prospectus under Securities Act Rules 163/433 was filed to correct the primary endpoint data for the KYSA-8 trial, revising the median improvement in the timed 25-foot walk (T25FW) to 46 percent at Week 16 and the p-value to 0.0003.

Financial and Strategic Analysis

As of December 17, 2025, Kyverna’s common stock closed at $6.95, reflecting a 32.13 percent decline and a trading volume of 1,293,503 shares on the Nasdaq Global Select Market (ticker: KYTX). On December 15, 2025, the company filed a preliminary prospectus (Rule 424(b)(5)) for a public offering of $100 million in common stock at $10.82 per share, with an underwriters’ overallotment option of $15 million. This capital raise, alongside a loan facility secured with Oxford Finance LLC for up to $150 million, is intended to fund ongoing clinical development, manufacturing scale-up, and general corporate purposes.

Market Position and Industry Context

Kyverna is among a limited number of companies focusing on translating CAR T-cell technology from oncology to autoimmune indications. Its strategy involves leveraging the durable B-cell depletion observed in hematological malignancies for application in chronic autoimmune diseases. While competition in the cell therapy sector is increasing, Kyverna’s multi-candidate pipeline and collaboration with Intellia position it to address a range of autoimmune diseases that currently lack approved treatment options.

tl;dr

On December 15, 2025, Kyverna presented Phase 2 KYSA-8 topline data for miv-cel in stiff person syndrome and filed for a $100 million stock offering at $10.82 per share. Its share price stood at $6.95 on December 17, 2025. The company corrected its p-value to 0.0003 in a December 17 free-writing prospectus and continues to advance registrational trials, with further readouts expected in early 2026. Future outlook will depend on clinical milestones, regulatory progress, and successful capital raises.